CAR-γδ T Cell Therapy for Hard-to-Treat Kidney Autoimmune Diseases
Treatments studied
Part of Immune system & allergy, Kidney & urinary, Skin, Women’s health & pregnancy clinical trials.
This early-stage trial tests a new type of immune cell therapy (CAR-γδ T cells) designed to treat three types of autoimmune kidney disease that haven't responded well to standard treatments. The goal is to see if this experimental therapy can reduce kidney damage and help patients avoid kidney failure.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Age 18–65 years old
- Diagnosed with one of three autoimmune kidney diseases (primary membranous nephropathy, lupus nephritis, or IgA nephropathy) confirmed by kidney biopsy within 18 months
- Disease has not responded adequately to standard immunosuppressive treatments (or has returned after initial improvement)
- Kidney function at minimum acceptable level (eGFR ≥30) and other major organs functioning reasonably well
- Not pregnant, not planning pregnancy for at least 1 year after cell infusion, and willing to use contraception
- No serious infections (HIV, hepatitis B/C), active cancer, recent major surgery, or significant heart/lung/brain conditions
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new immune therapy called CAR T-cells that target two proteins (CD19 and BCMA) to treat autoimmune diseases like lupus, nephrotic syndrome, and others. It is for people whose standard treatments have not worked well enough.
This early-stage trial tests a new type of cell therapy (CAR-T cells) designed to treat severe autoimmune diseases where the immune system attacks the body's own organs. The therapy targets specific immune cells (B cells) that may be causing the disease. It may help patients who haven't improved with standard treatments or can't tolerate them.
This trial tests a universal cell therapy called GT719 that targets CD19 on B cells to treat several immune-mediated kidney diseases, including IgA nephropathy, ANCA vasculitis, membranous nephropathy, and others. It may help people who have not responded well to standard treatments.
This trial tests a treatment where your own immune cells are modified to attack and destroy lupus-causing B cells. It's for people with lupus (SLE) that hasn't improved with standard treatments.
This trial tests a new CAR T-cell therapy (C-CAR168) for people with lupus nephritis that has not responded to standard treatments. It aims to see if this therapy can help control the disease.
This trial tests whether specially-engineered immune cells (CAR-T cells) can help people with certain autoimmune diseases that haven't gotten better with standard treatments. The cells are designed to target and remove faulty B cells that are causing the immune system to attack the body.
Hear when a new Membranous Nephropathy trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.